SG Americas Securities LLC Sells 10,289 Shares of Axsome Therapeutics, Inc. $AXSM

SG Americas Securities LLC lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 58.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,392 shares of the company’s stock after selling 10,289 shares during the quarter. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $1,249,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after buying an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp raised its position in shares of Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after buying an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Axsome Therapeutics by 38.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after buying an additional 84,151 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Axsome Therapeutics during the 1st quarter worth approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the period. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, Director Mark Coleman sold 6,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the sale, the director owned 35,140 shares of the company’s stock, valued at $8,092,742. This trade represents a 14.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Mark L. Jacobson sold 4,517 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $227.94, for a total value of $1,029,604.98. Following the sale, the chief operating officer owned 4,517 shares in the company, valued at $1,029,604.98. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 163,352 shares of company stock valued at $38,598,262. 20.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on AXSM. HC Wainwright reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday, June 4th. Guggenheim boosted their price objective on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Oppenheimer set a $280.00 target price on Axsome Therapeutics in a research note on Monday, May 4th. Robert W. Baird raised their target price on Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Finally, Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $258.95.

Axsome Therapeutics Price Performance

AXSM stock opened at $244.31 on Friday. The company has a 50 day simple moving average of $230.88 and a 200 day simple moving average of $192.09. The stock has a market cap of $12.57 billion, a price-to-earnings ratio of -65.50 and a beta of 0.60. Axsome Therapeutics, Inc. has a 1 year low of $96.09 and a 1 year high of $260.19. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics’s revenue for the quarter was up 57.4% on a year-over-year basis. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.31 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.